Clinical Outcomes Study of the Nexel Total Elbow
← catalyst calendarNCT02469662 · readout ≤ 3,421 d
Sponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
134estimated
Sites
11
Countries
Australia, Finland, France +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jun 2015 | actual | When the study began enrolling |
| Primary completion | Dec 2035 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2036 | estimated | The whole study's end, after follow-up |
| First posted | 2015-06-11 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Elbow Joint Destruction
- Post-traumatic Lesions
- Ankylosed Joints
- Advanced Rheumatoid Arthritis
- Joint Instability or Loss of Motion
- Acute Comminuted Articular Fracture of Elbow Joint Surfaces
- Bone Loss Contributing to Elbow Instability
- Bilateral Ankylosis From Causes Other Than Active Sepsis
- Post-traumatic Arthritis
- Degenerative Arthritis
Intervention
- Device: Nexel Total Elbow — also filed as Nexel Elbow, Nexel
Primary outcome
what the primary-completion date above is the date OFSurvivorship
measured 10 years
Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed